Impact of cumulative cisplatin dose in childhood nasopharyngeal carcinoma based on neoadjuvant chemotherapy response in the intensity-modulated radiotherapy era: a real-world study

Ya-Nan Jin†, Meng-Yun Qiang†, Meng-Meng Liu†, Zhi-Bin Cheng, Wang-Jian Zhang, Ian Ryan, Tia Marks, Ji-Jin Yao* and Liang-Ping Xia*

Abstract

Background: We aimed to comprehensively investigate the optimal cumulative cisplatin dose during concurrent chemoradiotherapy (CC-CCD) for locoregionally advanced nasopharyngeal carcinoma (CA-LANPC) with different tumor responses after neoadjuvant chemotherapy (NAC).

Methods: Patients with CA-LANPC who underwent NAC followed by cisplatin-based concurrent chemoradiotherapy were retrospectively analyzed. Evaluation of tumor response in patients was conducted by Response Evaluation Criteria for Solid Tumor (RECIST) 1.1 after two to four cycles NAC. Multivariate Cox proportional hazards models were used for prognosis. Recursive partitioning analysis (RPA) was conducted to classify participates and predict disease-free survival (DFS).

Results: One hundred and thirty-two patients with favorable response after NAC were included. The median CC-CCD was 163 mg/m² (IQR, 145–194 mg/m²), and 160 mg/m² was selected as the cutoff point to group patients into low and high CC-CCD groups (< 160 vs. ≥ 160 mg/m²). There was significant improvement in 5-year DFS (91.2% vs. 72.6%; P = 0.003) for patients receiving high CC-CCD compared to those receiving low CC-CCD. Multivariate analysis revealed that CC-CCD, T stage, and Epstein–Barr virus (EBV) DNA were independent prognostic factors for DFS (P < 0.05 for all). Patients were further categorized into two prognostic groups by RPA: the low-risk group (T1-3 disease with regardless of EBV DNA, and T4 disease with EBV DNA < 4000 copy/mL), and the high-risk group (T4 disease with EBV DNA ≥ 4000 copy/mL).
In children and adolescents (age ≤ 18 years), nasopharyngeal carcinoma (NPC) is rare and accounts for only 1–2% of all NPC cases [1, 2]. Given the rarity of childhood NPC and the difficulty of conducting relevant prospective studies, treatment of childhood NPC traditionally follows guidelines applied to adults. The National Comprehensive Cancer Network (NCCN) Guidelines recommended neoadjuvant chemotherapy (NAC) followed by concurrent chemoradiotherapy (CCRT) as level 2A evidence for locoregionally advanced NPC (LANPC) [3]. At present, the cumulative cisplatin dose during concurrent chemoradiotherapy (CC-CCD) has been considered an important treatment for LANPC. However, the optimal cutoff value of CC-CCD in NPC remains controversial. The study by Peng et al. [4] showed 200 mg/m² CC-CCD may suffice in achieving survival benefits. While Lv et al. found 160 mg/m² CC-CCD may be sufficient to precipitate beneficial antitumor effects after NAC [5]. Of note, these findings were mainly limited to adult patients (age > 18 years), while patients aged 18 years and younger were excluded from these studies [4, 5]. Compared to adult patients, tolerance and sensitivity to chemotherapy in children and adolescents with LANPC (CA-LANPC) are markedly different [6, 7], and the optimal value of CC-CCD for CA-LANPC remains unclear.

NAC, given before CCRT, has been widely proven to be a feasible neoadjuvant treatment with satisfactory efficacy in LANPC during the past decade [8–10]. However, patients treated with the same NAC regimen can still show substantial heterogeneity in tumor response. Generally, patients who achieved complete response (CR)/partial response (PR) after two to four cycles of NAC were more likely to have increased sensitivity to NAC compared to those who suffered stable disease (SD)/disease progression (PD). Consequently, patients who suffered SD/PD after NAC had inferior locoregional relapse-free survival (LRFS) and disease-free survival (DFS) compared to patients reaching CR/PR after NAC [11, 12]. We therefore speculate that the optimal CC-CCD is likely distinct for patients with varied NAC responses. However, there is a lack of systematic investigation to evaluate the optimal CC-CCD in CA-LANPC with varied NAC response.

Given this evidence, we conducted a real-world research on CA-LANPC to elucidate the significance of CC-CCD in survival outcomes based on their tumor responses after two to four cycles NAC. Moreover, the therapeutic values of high or low CC-CCD were compared in various patient risk groups. Our results may provide oncologists better treatment strategies for CA-LANPC.

**Materials and methods**

**Patients cohort**

We retrospectively investigated the NPC-specific database which was provided and approved by the big-data platform at our center between September 2007 and April 2018. Eligibility criteria for our study included: (a) confirmed pathological NPC at III–IVB NPC (7th edition of the AJCC [American joint Committee on Cancer] staging system [13]); (b) no other malignant disease; (c) age ≤ 18 years old at initial diagnosis; (d) first line NAC followed by cisplatin-based CCRT; (e) available imaging evaluation data after 2–4 cycles of NAC; (f) treated with intensity-modulated radiotherapy (IMRT); and (g) adequate organ function. A series of routine exams were conducted on each patient prior to treatment. Serum Epstein–Barr virus (EBV) DNA was quantitatively measured by polymerase chain reaction prior to treatment. This study received approval from the Research Ethics Committee at our institution. Patients informed consents were obtained for the entire cohort.

**Treatment and evaluation of NAC response**

NAC followed by cisplatin-based CCRT was delivered to each patient. NAC regimens included PF [5-fluorouracil (800–1000 mg/m², by 120-h continuous intravenous infusion) and cisplatin (80–100 mg/m² on day 1)]. TP [cisplatin (75 mg/m² on day 1) and docetaxel (75 mg/m² on day 1)], TPF [docetaxel (60 mg/m² on day 1), cisplatin (60 mg/m² on day 1), and 5-fluorouracil (500–600 mg/m², by 120-h continuously intravenous infusion)], and GP [gemcitabine (1000 mg/m² on day 1, 8) and cisplatin (80 mg/m² on day 1)]. Two to four cycles NAC were administered. In this study, we defined progression-free survival (PFS) as the time from the start date of NAC to the date of progression or death from any cause (censored at the end of the study period). The primary endpoint was DFS, defined as the time from the start date of NAC to the date of disease progression or death from any cause (censored at the end of the study period).

**Conclusions:** CC-CCD was a positive prognostic factor for responders after NAC in CA-LANPC. Furthermore, CC-CCD ≥ 160 mg/m² could significantly improve DFS in the high-risk group with CA-LANPC, but the benefit of high CC-CCD in the low-risk group needs further study.

**Keywords:** Nasopharyngeal carcinoma, Cumulative cisplatin dose, Children and adolescents, Tumor response, Neoadjuvant chemotherapy

---

**EBV DNA ≥ 4000 copy/mL. Significant 5-year DFS improvement was observed for the high-risk group (P = 0.004) with high CC-CCD. However, DFS improvement was relatively insignificant in the low-risk group (P = 0.073).**

**Conclusions:** CC-CCD was a positive prognostic factor for responders after NAC in CA-LANPC. Furthermore, CC-CCD ≥ 160 mg/m² could significantly improve DFS in the high-risk group with CA-LANPC, but the benefit of high CC-CCD in the low-risk group needs further study.

**Keywords:** Nasopharyngeal carcinoma, Cumulative cisplatin dose, Children and adolescents, Tumor response, Neoadjuvant chemotherapy
administered at three-week intervals. Another MRI was conducted for all patients at 2 to 3 weeks after the final NAC cycle. Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) [14], which is widely used to evaluate the treatment of tumor response in various solid tumors [15, 16], was used to evaluate tumor response to NAC. In the current study, patients experiencing CR/PR were classified as favorable responders, and patients suffering PD/SD were classified as unfavorable responders.

IMRT was delivered to all patients on a conventional schedule (one fraction per day, five days per week). Prescribed doses for CA-LANPC complied with our center’s guidelines. In detail, prescribed doses of the planning tumor volume (PTV) for gross tumor volume (GTVn) was 66–72 Gy; PTV of the involved cervical lymph nodes (GTVnd) was 64–70 Gy; PTV of high-risk clinical target volume (CTV1) was 60–64 Gy; and PTV for low-risk clinical target volume (CTV2) was 50–54 Gy in 30 to 33 fractions. The detailed introduction on IMRT planning was reported in our previous studies [17, 18]. Concurrent cisplatin-based chemotherapy was administered weekly (30–40 mg/m² each week) or tri-weekly (80–100 mg/m² every 3 weeks).

Outcome and follow-up

DFS, given as the time from the NAC initiation to the date of disease progression or until any causes of death, was the primary endpoint. Other endpoints included overall survival (OS) (given as the time from the NAC initiation to the day of death), distant metastasis-free survival (DMFS) (given as the time from the NAC initiation to the day of distant metastasis), and LRFS (given as the time from the NAC initiation to the day of local/regional recurrence). Patients were monitored every 3 month during the first 2 years, every 6 months during the 3rd to 5th years, and once a year thereafter.

Statistical analysis

Host factors [i.e. sex, age, smoking history, BMI (body mass index), and EBV DNA], tumor factors (i.e. T stage, N stage, and overall stage), and treatment factors [i.e. cumulative cisplatin dose during NAC (NAC-CCD), NAC cycles, NAC regimens, adjuvant chemotherapy, radiation dose, and CC-CCD] were all considered as covariates. Age, radiation dose, BMI, and NAC-CCD were transformed into categorical variables according to their median splits. As described in previous studies [19], patients were categorized into low- and high-EBV DNA groups based on the cutoff value of 4000 copies/mL. Since the median NAC-CCD was 181.8 mg/m² (interquartile range [IQR], 141.7–221.1 mg/m²), 180 mg/m² (< 180 vs. ≥ 180 mg/m²) was set as the cutoff point to classify patients into low- and high-NAC-CCD groups. Previously peer-reviewed data suggested a CC-CCD of 160 mg/m² or 200 mg/m² as necessary to confer survival for LANPC patients receiving NAC plus CCRT [4, 5, 20]. Therefore, we categorized patients into three groups based on CC-CCD (<160 mg/m², 160–200 mg/m², and >200 mg/m²), and survival outcomes between different CC-CCD groups were compared. The clinicopathologic factors were compared using χ² test for frequencies.

Cumulative survival rates were assessed using the Kaplan–Meier method and compared using a log-rank test. Multivariate Cox regression analysis confirmed the role of CC-CCD in DFS when adjusted for other possible factors. To attain the patients most likely to benefit from high CC-CCD, we performed individual comparisons of low- and high-CC-CCD for each risk group based on recursive partitioning analysis (RPA). The statistical significance was set as P<0.05, and statistical tests were two-sided. All models were generated using R version 3.4.2 (http://www.r-project.org/).
Results

Patient characteristics

Figure 1 presents the patient flow diagram. A total of 147 consecutive CA-LANPC patients who received NAC followed by CCRT were involved in this study. After two to four cycles of NAC, 15 patients (10%) suffered unfavorable responses (SD/PD), and 132 patients (90%) achieved favorable tumor response (CR/PR). The baseline characteristics of the 132 favorable responders were shown in Table 1. The percentages of patients grouped as stage III, IVA, and IVB were 27.3%, 36.4%, and 36.4%, respectively. A total of 60 (45%), 66 (50%) and 6 (5%) patients received two, three and four cycles NAC, respectively. The median radiation dose was 6800 cGy (IQR, 6600–7000 cGy). The median time to follow-up was 63.7 months (IQR, 40.7–88.9 months). During the follow-up, four patients (3%) exhibited locoregional recurrence, 17 (13%) developed distant metastases, and 14 (11%) died. For the entire group, the 5-year rates of DFS, DMFS, OS, and LRFS were 83.9% (95% CI 77.8–90.4%), 87.7% (95% CI 82.3–93.6%), 89.3% (95% CI 83.9–95.0%), and 97.5% (95% CI 94.9–100%) respectively.

Prognostic value of CC-CCD in favorable responders

The median CC-CCD to the favorable responders was 163 mg/m² (IQR, 145–194 mg/m²), and the clinical characteristics were summarized in 40-mg intervals (Additional file 1: Table S1). Overall, 52 patients (39%) received CC-CCD < 160 mg/m², 50 patients (69%) received a CC-CCD of 160–200 mg/m², and 30 participants (22%) received CC-CCD > 200 mg/m². No significant differences were noted with regard to sex, age, and TNM stage among each of the three groups (P > 0.05 for all; Additional file 1: Table S1). As shown in Additional file 2: Fig. S1, patients receiving CC-CCD of 160–200 mg/m² exhibited significantly higher 5-year DFS rates than participants who received CC-CCD < 160 mg/m² (94.0% vs. 72.6%, P = 0.010). Yet, no significant outcomes were seen in patients receiving CC-CCD > 200 mg/m² and 160–200 mg/m² for 5-Year DFS (P = 0.261). Thus, we combined these above groups into one group with a CC-CCD ≥ 160 mg/m². We selected 160 mg/m² as the cut-off point to categorize patients into low- and high-CC-CCD group (<160 mg/m² vs. ≥160 mg/m²). The high CC-CCD group shared similar clinical characteristics with the low CC-CCD group except for NAC regimens, with those patients treated with NAC regimens of TPF were most likely to receive high CC-CCD (P < 0.001; Table 1).

The high CC-CCD group showed better 5-year DFS (91.2% vs. 72.6%; P = 0.003; Additional file 3: Fig. S2A) and 5-year DMFS (93.7% vs. 78.4%; P = 0.006; Additional
Table 1  Baseline characteristics of study cohort (n = 132)

| Characteristic          | Entire cohort (n = 132) | CC-CCD, mg/m² | P valuea |
|-------------------------|-------------------------|---------------|----------|
|                         |                          | < 160 (n = 52, %) | ≥ 160 (n = 80, %) |          |
| Sex                     |                          |               |          |
| Male                    | 92 (69.7)               | 39 (75.0)     | 53 (66.2) | 0.354    |
| Female                  | 40 (30.3)               | 13 (25.0)     | 27 (33.8) |          |
| Age, years              |                          |               |          |
| ≤ 15                    | 69 (52.3)               | 25 (48.1)     | 44 (55.0) | 0.494    |
| < 15                    | 63 (47.7)               | 27 (51.9)     | 36 (45.0) |          |
| Smoking history         |                          |               |          |
| No                      | 123 (93.2)              | 46 (88.5)     | 77 (96.2) | 0.170    |
| Yes                     | 9 (6.8)                 | 6 (11.5)      | 3 (3.8)  |          |
| BMI, m²                 |                          |               |          |
| ≤ 1.45                  | 64 (48.5)               | 22 (42.3)     | 42 (52.5) | 0.310    |
| > 1.45                  | 68 (51.5)               | 30 (57.7)     | 38 (47.5) |          |
| EBV DNA, copy/mL        |                          |               |          |
| < 4000                  | 52 (39.4)               | 17 (32.7)     | 35 (43.7) | 0.293    |
| ≥ 4000                  | 80 (60.6)               | 35 (67.3)     | 45 (56.3) |          |
| T stageb                |                          |               |          |
| T1                      | 1 (0.8)                 | 1 (1.9)       | 0 (0)    | 0.281    |
| T2                      | 4 (3.0)                 | 1 (1.9)       | 3 (3.8)  |          |
| T3                      | 59 (44.7)               | 27 (51.9)     | 32 (40.0) |          |
| T4                      | 68 (51.5)               | 23 (44.2)     | 45 (56.3) |          |
| N stageb                |                          |               |          |
| N0                      | 1 (0.8)                 | 1 (1.9)       | 0 (0)    | 0.165    |
| N1                      | 18 (13.6)               | 8 (15.4)      | 10 (12.5) |          |
| N2                      | 65 (49.2)               | 29 (55.8)     | 36 (45.0) |          |
| N3                      | 48 (36.4)               | 14 (26.9)     | 34 (42.5) |          |
| Overall stageb          |                          |               |          |
| III                     | 36 (27.3)               | 19 (36.5)     | 17 (21.3) | 0.114    |
| IVA                     | 48 (36.4)               | 19 (36.5)     | 29 (36.2) |          |
| IVB                     | 48 (36.4)               | 14 (26.9)     | 34 (42.5) |          |
| NAC cycles              |                          |               |          |
| 2                       | 60 (45.5)               | 30 (57.7)     | 30 (37.5) | 0.062    |
| 3                       | 66 (50.0)               | 21 (40.4)     | 45 (56.3) |          |
| 4                       | 6 (4.5)                 | 1 (1.9)       | 5 (6.2)  |          |
| NAC regimens            |                          |               | < 0.001  |
| TPF                     | 73 (55.3)               | 18 (34.6)     | 55 (68.8) |          |
| TP                      | 20 (15.2)               | 13 (25.0)     | 7 (8.8)  |          |
| PF                      | 35 (26.5)               | 21 (40.4)     | 14 (17.5) |          |
| GP                      | 4 (3.0)                 | 0 (0.0)       | 4 (5.0)  |          |
| Adjuvant chemotherapy   |                          |               | 0.575    |
| No                      | 129 (97.7)              | 50 (96.1)     | 79 (98.7) |          |
| Yes                     | 3 (2.3)                 | 2 (3.9)       | 1 (1.3)  |          |
| NAC-CCD, mg/m²          |                          |               | 0.112    |
| < 180                   | 62 (47.0)               | 29 (55.8)     | 33 (41.3) |          |
| ≥ 180                   | 70 (53.0)               | 23 (44.2)     | 47 (58.7) |          |
| Radiation dose, cGy     |                          |               | 0.386    |
| < 6800                  | 64 (49.6)               | 22 (44.0)     | 42 (53.2) |          |
| ≥ 6800                  | 65 (50.4)               | 28 (56.0)     | 37 (46.8) |          |

CC-CCD cumulative cisplatin dose during concurrent chemoradiotherapy, BMI body mass index, EBV Epstein–Barr virus, NAC neoadjuvant chemotherapy, TPF cisplatin with 5-fluorouracil and toxoids, TP cisplatin with toxoids, PF cisplatin with 5-fluorouracil, GP cisplatin with gemcitabine, NAC-CCD cumulative cisplatin dose during concurrent chemoradiotherapy.
file 3: Fig. S2B) than the low CC-CCD group. There was a distinct trend toward improved 5-year OS (94.8% vs. 81.7%; \( P = 0.071 \); Additional file 3: Fig. S2C) when comparing high CC-CCD group with low CC-CCD group. In contrast, there were no significant differences in the 5-year DFS (85.3% vs. 82.2%, \( P = 0.472 \); Additional file 4: Fig. S3A), DMFS (91.3% vs. 83.8%, \( P = 0.138 \); Additional file 4: Fig. S3B), OS (90.9% vs. 86.9%, \( P = 0.502 \); Additional file 4: Fig. S3C) and LRFS (96.9% vs. 98.2%, \( P = 0.406 \); Additional file 4: Fig. S3D) rates between high NAC-CCD group and low NAC-CCD group. In multivariate analysis, higher CC-CCD was an independent favorable prognostic factor for DFS (HR, 0.26; 95% CI 0.10–0.65; \( P = 0.004 \)) and DMFS (HR, 0.28; 95% CI

![Fig. 3](#)

**Fig. 3** Kaplan–Meier survival curves for the high-risk group and low-risk group. A Disease-free survival, B distant metastasis-free survival, C overall survival, and D locoregional relapse-free survival high-risk group, T4 disease with EBV DNA \( \geq 4000 \) copy/mL; low-risk group, T1–3 disease regardless of EBV DNA and T4 disease with EBV DNA < 4000 copy/mL.
0.10–0.81; P = 0.018). Apart from CC-CCD, T stage and EBV DNA were also found to be significantly associated with DFS and DMFS (P < 0.05 for all; Table 2). Although advanced T stage was significantly associated with poor OS (HR, 2.94; 95% CI 1.01–4.27; P = 0.046), there was only a borderline significance of EBV DNA for predicting OS (HR, 3.72; 95% CI 0.83–16.67; P = 0.057; Table 2).

Role of CC-CCD based on RPA model

Patients were further categorized into variable risk groups based on T stage and EBV DNA given the DFS endpoint. As shown in Fig. 2, patients with CA-LANPC were segregated into 4 classes based on RPA. However, not all intergroup (e.g. class 1 to class 4) prognoses were significantly different (Additional file 5: Fig. S4). Patients from class 4 had the poorest DFS (5-year DFS, 70.8%) among the four groups and the DFS rates of class 1, 2, and 3 were comparable (class 1 vs. 2, P = 0.247; class 1 vs. 3, P = 0.346; class 2 vs. 3, P = 0.659; Additional file 5: Fig. S4), and therefore these three categories were merged. Consequently, our final RPA model categorized participants into two prognostic categories: low-risk group (T1–T3 with low or high EBV DNA, and T4 with low EBV DNA; n = 90) and high-risk group (T4 with high EBV DNA; n = 42), with corresponding 5-year DFS rates of 89.9% and 70.8%, respectively (P = 0.011; Fig. 3A).

Table 2 Multivariate analysis of prognostic factors for the entire group

| Endpoint | Variable | HR | 95% CI for HR | P valuea |
|----------|----------|----|---------------|----------|
| DFS      | CC-CCD (< 160 vs. ≥ 160 mg/m²) | 0.26 | 0.10–0.65 | 0.004 |
|          | T stage (T1–3 vs. T4) | 2.66 | 1.07–6.62 | 0.036 |
|          | EBV DNA (<4000 vs. ≥ 4000 copy/mL) | 3.35 | 1.11–10.16 | 0.032 |
|          | Smoking history (no vs. yes) | 2.53 | 0.72–8.92 | 0.148 |
| DMFS     | CC-CCD (< 160 vs. ≥ 160 mg/m²) | 0.28 | 0.10–0.81 | 0.018 |
|          | T stage (T1–3 vs. T4) | 2.34 | 1.03–5.62 | 0.041 |
|          | EBV DNA (<4000 vs. ≥ 4000 copy/mL) | 3.27 | 1.02–9.60 | 0.046 |
|          | Smoking history (no vs. yes) | 3.50 | 0.97–12.64 | 0.056 |
| OS       | T stage (T1–3 vs. T4) | 2.94 | 1.01–4.27 | 0.046 |
|          | EBV DNA (<4000 vs. ≥ 4000 copy/mL) | 3.72 | 0.83–16.67 | 0.057 |

*HR hazards ratio, 95% CI 95% confidence interval, CC-CCD cumulative cisplatin dose during concurrent chemoradiotherapy, EBV Epstein-Barr virus, DFS disease-free survival, DMFS distant metastasis-free survival, OS overall survival

*P values were calculated using an adjusted Cox proportional hazards model
The low-risk group showed significantly improved 5-year DMFS (92.2% vs. 78.1%; \( P = 0.039 \); Fig. 3B) and OS rates (95.4% vs. 75.7%; \( P = 0.004 \); Fig. 3C) compared with the high-risk group. But no statistical variation was observed when comparing 5-year LRFS in the low-risk group versus the high-risk group (98.9% vs. 93.9%; \( P = 0.280 \); Fig. 3D). Subgroup analyses were performed in various risk groups based on RPA models to assess the survival benefit of CC-CCD (Fig. 4). In the high-risk group, participants who received CC-CCD \( \geq 160 \text{ mg/m}^2 \) were seen to have significantly higher 5-year DFS rates than participants who received CC-CCD < 160 mg/m\(^2\) (85.7% vs. 42.9%; \( P = 0.004 \); Fig. 4A). Although participants who received CC-CCD \( \geq 160 \text{ mg/m}^2 \) were more inclined to have superior 5-year DFS (94.2% vs. 84.0%; \( P = 0.073 \); Fig. 4B) in the low-risk group, this did not reach statistical significance.

Severe acute and late toxicities

During chemoradiotherapy, severe (grade 3–4) mucositis was observed in 43.2% (57/132) of patients, and severe nausea was noted in 17.4% (23/132) of patients. Severe hematological toxicities included leucopenia (35/132; 26.5%), followed by neutropenia (18/132; 13.6%), anemia (5/132; 3.8%), and thrombocytopenia (2/132; 1.5%) during concurrent chemotherapy. During the follow-up, 115 (87%; 115/132) patients' late toxicities were available. Severe late effects mainly included xerostomia (9.6%; 11/115), ototoxicity (7.8%; 9/115), neck fibrosis (5.2%; 6/115) and hypothyroidism (2.6%; 3/115). Overall, the rates of acute and late toxicities were comparable between high and low CC-CCD group (\( P > 0.05 \) for all; Table 3).

**Discussion**

Based on our understanding, this is one of the first studies to assess the prognostic value of CC-CCD for CA-LANPC treated with NAC plus CCRT, especially for those patients who received favorable responses after NAC. Our results suggested that treatment with NAC and CCRT resulted in excellent outcomes (5-year OS, 89.3%) among CA-LANPC with favorable responses to NAC. Patients treated with CC-CCD < 160 mg/m\(^2\) indicated statistically diminished 5-year DFS compared to participants receiving CC-CCD of 160–200 mg/m\(^2\). However, no significant differences were observed between CC-CCD > 200 mg/m\(^2\) and 160–200 mg/m\(^2\) for DFS. Further analysis revealed CC-CCD \( \geq 160 \text{ mg/m}^2 \) was associated with better DFS in high-risk patients among CA-LANPC; however, the benefit of CC-CCD \( \geq 160 \text{ mg/m}^2 \) in low-risk patients requires further study.

The combination of NAC and CCRT has been studied on adults in multiple randomized clinical trials [21, 22]. An updated Meta-Analysis from the Nasopharyngeal Collaborative Group indicated that NAC plus CCRT was superior to just CCRT for disease control, locoregional control, and distant control in patients with LANPC [10]. However, randomized clinical trials have yet to assess childhood NPC, and high-level evidence on the treatment of children's NPC is minimal. Over the past ten years, several small cohort studies have reported the survival outcomes of CA-LANPC after treatment with NAC.
plus CCRT. Overall, the 5-year DFS and DMFS rates varied from 56 to 79% and from 78 to 86%, respectively [23–26]. In the current study, treatment with NAC and CCRT showed great outcomes among CA-LANPC, with 5-year DFS rate of 83.9% and DMFS rate of 87.7%, respectively. In line with our results, a recent ARAR0331 study [27] found that the 5-year DFS rate and DMFS rate estimates were 84.3% and 89.2%, respectively. These data suggest that NAC combined with CCRT is a good treatment in the management of CA-LANPC.

An important note to address is that multiple NAC regimens (e.g. TP, PF, TPF, and GP) were adopted in the present study, which may confound the survival outcomes. However, the ideal NAC regimen was not established during the study period. Although the high-intensity TPF regimen appears to confer more benefits than the TP or PF combinations [8, 9, 28], statistically significant survival differences between neoadjuvant regimens were not detected by pooled analysis [22]. Neoadjuvant GP regimen is commonly used in most adult centers based on the phase III trial results [16, 29]. However, only four patients (3%) used the GP regimen in our study, because the GP regimen was still in the preliminary stage of NPC research during the study period. Also, there was insufficient clinical evidence to support its widespread use at the time. It is widely acknowledged that NAC has the advantages of micro-metastases eradication [10]. However, NAC may prolong the duration of treatment and reduce the compliance in subsequent CCRT [10]. The randomized controlled trials usually used two to three cycles of NAC before CCRT [8, 28, 30], but it remains unclear how many NAC cycles would be beneficial for patients. In our center, the idea of using NAC is mainly based on the response of NAC and the experience of clinicians. Once patients obtained CR/PR after NAC, the RT intervention would be considered as soon as possible to avoid RT delay and reduce the effect of treatment outcomes. Overall, all NAC regimens included in our study were consistent with the NCCN Guidelines [3], and the optimal NAC cycles remained unclear during the study period. To reduce the influence of the above factors on the results of the study, NAC-CCD, NAC cycles, and NAC regimens were all analyzed in the multivariate Cox proportional hazards models.

Patients who experienced favorable response after NAC had better treatment outcomes compared with patients who experienced unfavorable response after NAC [11, 12]. It can be speculated that the optimal CC-CCD used during RT may be different for patients with alternative responses after NAC. And the results of optimal CC-CCD would be affected if the NAC response was not considered. Recently, Liu et al. [31] attempted to determine an optimal level of CC-CCD in CCRT for NPC patients who completed CR/PR after NAC. They found participants receiving > 200 mg/m^2 of CC-CCD after achieving CR/PR post NAC showed improved 3-year DFS and DMFS rates over participants receiving CC-CCD < 100 mg/m^2. However, no significant distinctions were found between > 200 mg/m^2 and 101–200 mg/m^2 for all outcomes. Yet, Lv et al. [5] reported 200 mg/m^2 of CC-CCD did not improve survival in LANPC, and 160 mg/m^2 of CC-CCD may be sufficient for LANPC patients treated with NAC combined with CCRT. In the current study, the survival outcomes among CC-CCD < 160 mg/m^2, 160–200 mg/m^2, and >200 mg/m^2 were compared in CA-LANPC. Our data indicated that CC-CCD ≥160 mg/m^2 was an independent protective prognostic factor for superior survival outcomes. However, no significant improvements for survival were seen in participants receiving >200 mg/m^2 of CC-CCD compared to participants receiving 160–200 mg/m^2 of CC-CCD. This is in accordance with the study reported by Lv and his colleagues [5].

To confirm which patients benefit from high CC-CCD, previous studies usually use multivariate Cox regression analysis to elucidate all relevant prognostic factors [4, 5, 31]. However, these prognostic factors are often combined with other independent factors. To avoid the interaction between these factors and combine prognostic factors with risk of disease progression, all relevant risk factors were included in the RPA model for risk stratification analysis. We then analyzed the role of CC-CCD by hierarchical analysis through RPA, which stratified participants into subgroups with similar survival patterns. As a result, the RPA model then categorized CA-LANPC into different risk groups based on risk factors. In further stratified analysis, we found that the benefit of high CC-CCD is more obvious in the high-risk group. For the low-risk group, participants who received high CC-CCD were seen as having a distinct trend for superior 5-year DFS (94.2% vs. 84.0%; P=0.073; Fig. 4B), but it was not statistically significant. Although the difference was nonsignificant in the low-risk group, they might also benefit from CC-CCD ≥160 mg/m^2. Overall, larger cases and longer follow-up time are required for further study on the benefit of high CC-CCD for the low-risk group.

It is important to mention, most studies acknowledge T1/T2 and N0–1 as the early stages of cancer [32]. In this study, however, only 5 patients (3.8%) were staged at T1–2 and 19 (14.4%) were staged at N0–1 since the main focus was on the LANPC (stage III–IVB). Therefore, we combined T1–3 and N0–2 due to the limited number of patients with T1–2 and N0–1, respectively. Our findings suggested T stage was an independent prognostic factor in multivariate analysis. However, we failed to observe significance associated with N stage in the present study.
This observation may be due to the limited sample size. In addition, nearly 80% of patients staged at N2 were in the N0–2 group. This overlap may make it more difficult to recognize the survival difference between N0–2 and N3 disease.

In adult patients with NPC, the overall reported response rate of NAC ranged from 67 to 77% [11, 32]. The response rate after NAC for two to four cycles was 90% in our study, which is higher than most of the other studies in adult patients. Consistent with our study [33], another prospective study (NPC-91-GPOH) reported the overall response rate to three courses of NAC (methotrexate, cisplatin, and 5-fluorouracil) was 91% in NPC children and adolescents. It's important to note that more than half of patients received an NAC with TPF regimen, and approximately 40% received NAC with the TP/PF regimen in the current study, which are the most common and effective NAC regimens used in other series [18–22]. Consequently, it is reasonable to speculate that childhood and adolescent NPC has increased sensitivity to NAC compared to adult patients. However, latent mechanisms leading to the differences in NAC sensitivity between children and adults needs further study.

We should note our study has important limitations. Foremost, all utilized data was provided by one center in an NPC endemic area, thus reducing the ability to externally validate with data from other hospitals. Thus, our findings still need to be further validated. Next, limited by the small sample size of SD/PD patients after NAC (n = 15) in our study, the optimal CC-CCD for SD/PD patients was lacking. However, NPC in children and adolescents is rare, and identifying more may be a challenge since only 1–2% of all diagnosed cases of NPC were classified as childhood NPC in the endemic region. Finally, selection bias was an inevitability given the retrospective nature of this study. However, hierarchical analysis was employed to analyze the impact of CC-CCD in different risk patients, which is helpful to reduce the influence of confounding factors on the study results.

Conclusions
In conclusion, CA-LANPC patients who received CC-CCD ≥ 160 mg/m² showed superior DFS and DMFS rates compared to patients receiving CC-CCD < 160 mg/m² while no significant variation was noted when comparing patients in the 160–200 mg/m² and > 200 mg/m² groups. Furthermore, we found that the benefit of CC-CCD ≥ 160 mg/m² is more obvious in the high-risk group, but whether the low-risk group could benefit from CC-CCD ≥ 160 mg/m² requires further study. Our results may contribute to improved guidance on individualized treatment strategies for CA-LANPC, especially for those patients who achieved CR/PR after NAC. However, a prospective study is still needed to verify our findings in the future.

Abbreviations
NPC: Nasopharyngeal carcinoma; NCCN: National Comprehensive Cancer Network; LANPC: Locoregionally advanced nasopharyngeal carcinoma; NAC: Neoadjuvant chemotherapy; CCRT: Concurrent chemoradiotherapy; CA-LANPC: Children and adolescents with locoregionally advanced nasopharyngeal carcinoma; RT: Radiotherapy; CC-CCD: Cumulative cisplatin dose during concurrent chemoradiotherapy; AJCC: American joint Committee on cancer; CR: Complete response; PR: Partial response; SD: Stable disease; PD: Disease progression; DFS: Disease-free survival; IMRT: Intensity-modulated radiotherapy; MRI: Magnetic resonance imaging; CT: Computed tomography; PET: Positron emission tomography; EBV: Epstein–Barr virus; PF: Cisplatin plus 5-fluorouracil; TP: Docetaxel plus cisplatin; TPF: Docetaxel, cisplatin, and 5-fluorouracil; GP: Gemcitabine plus cisplatin; RECIST: Response Evaluation Criteria in Solid Tumors; OS: Overall survival; DMFS: Distant metastasis-free survival; LRFS: Locoregional relapse-free survival; RPA: Recursive partitioning analysis; BMI: Body mass index; NAC-CCD: Cumulative cisplatin dose during neoadjuvant chemotherapy.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12935-021-02281-4.

Acknowledgements
Not applicable.

Authors’ contributions
LPX, JYJ, and YNJ conceptualized and designed the study. YNJ, MYQ, MML, and ZBC acquisitioned the data. The analysis and interpretation of data was done by WJZ and JJY. The manuscript was drafted for important intellectual content by YNJ, MYQ, MML, and ZBC, and revised by IR, TM, JYJ, and LPX. The final approval of the manuscript was done by LPX and JYJ. All authors critically reviewed and contributed to the final manuscript. All authors read and approved the final manuscript.

Funding
This work was supported by grants from the National Natural Science Foundation of China (No. 81901699 and 81773035), the Health and Medical...
Collaborative Innovation Project of Guangzhou City, China (201803040003), and Guangdong Medical Science and Technology Research Fund (No. C2018063).

Availability of data and materials
Key raw data were uploaded onto the Research Data Deposit public platform (RDD), with the approval RDD number of RDDA2021230562.

Declarations

Ethics approval and consent to participate
Written informed consent was obtained from all subjects who participated in the study. And this study was approved by the Institutional Review Board of Sun Yat-sen University Cancer Center.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1VIP Region, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510060, Guangdong, China. 2Department of Head and Neck Radiotherapy, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou 310022, Zhejiang Province, China. 3Malignant and Sarcoma Medical Oncology Unit, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, 651 Dongfeng Road East, Guangzhou 510060, China. 4The Cancer Center of the Fifth Affiliated Hospital of Sun Yat-sen University, Guangdong Provincial Key Laboratory of Biomedical Imaging, Zhuhai S19000, Guangdong, China. 5Department of Medical Statistics, School of Public Health, Sun Yat-sen University, Guangzhou 510080, Guangdong, China. 6Department of Environmental Health Sciences, School of Public Health, University at Albany, State University of New York, Rensselaer 12144, USA.

Received: 2 September 2021 Accepted: 19 October 2021

References

1. Dourthe ME, Bolle S, Téman S, Jouin A, Claude L, Reguerre Y, et al. Childhood nasopharyngeal carcinoma: state-of-the-art, and questions for the future. J Pediatr Hematol Oncol. 2018;40(2):85–92.
2. Sultan I, Casanova M, Ferrari A, Rihani R, Rodríguez-Galindo C. Differential features of nasopharyngeal carcinoma in children and adults: a SEER study. Pediatr Blood Cancer. 2010;55(2):279–84.
3. Pfister DG, Spencer S, Adelstein D, Atkins D, Anzai Y, Brizel DM, et al. Head and neck cancers, version 2.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2020;18(7):873–98.
4. Peng H, Chen L, Zhang Y, Li WF, Mao YP, Zhang F, et al. Prognostic value of the cumulative cisplatin dose during concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a secondary analysis of a prospective phase III clinical trial. Oncologist. 2016;21(11):1369–76.
5. Lv JW, Qi ZY, Zhou GQ, He XJ, Chen YP, Mao YP, et al. Optimal cumulative cisplatin dose in nasopharyngeal carcinoma patients receiving additional induction chemotherapy. Cancer Sci. 2018;109(3):751–63.
6. Chen BB, Lu SY, Peng H, Sun FF, Zhu J, Wang J, et al. Comparison of long-term outcomes and sequelae between children and adult nasopharyngeal carcinoma treated with intensity modulated radiation therapy. Int J Radiat Oncol Biol Phys. 2020;106(4):948–56.
7. Downing NL, Widsten S, Wong P, Petrik DW, Hara W, Le QT. Comparison of treatment results between adult and juvenile nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2009;75(4):1064–70.
8. Sun Y, Li WF, Chen NY, Zhang N, Hu GQ, Xie FY, et al. Induction chemotheraphy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial. Lancet Oncol. 2016;17(11):1509–20.
9. Gao SM, Yang Q, Guo L, Mai HQ, Mo HY, Cao KJ, et al. Neoadjuvant chemoradiotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase III multicentre randomised controlled trial. Eur J Cancer. 2017;75:14–23.
10. Ribassin-Majed L, Marguet S, Lee AWM, Ng WT, Ma J, Chan ATC, et al. What is the best treatment of locally advanced nasopharyngeal carcinoma? An individual patient data network meta-analysis. J Clin Oncol. 2017;35(5):498–505.
11. Liu LT, Tang LQ, Chen QY, Zhang L, Guo SS, Guo L, et al. The prognostic value of plasma Epstein–Barr viral DNA and tumor response to neoadjuvant chemotherapy in advanced-stage nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2015;93(4):862–9.
12. Peng H, Chen L, Zhang Y, Li WF, Mao YP, Liu X, et al. The tumour response to induction chemotheraphy has prognostic value for long-term survival outcomes after intensity-modulated radiation therapy in nasopharyngeal carcinoma. Sci Rep. 2016;6:24835.
13. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17:1471–4.
14. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.
15. Coy HJ, Douek ML, Ruchalski K, Kim HJ, Gutierrez A, Patel M, et al. Components of radiologic progressive disease defined by RECIST 1.1 in patients with metastatic clear cell renal cell carcinoma. Radiology. 2019;292(1):103–9.
16. Zhang L, Huang Y, Hong S, Yang Y, Yu G, Jia J, et al. Gemicitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial. Lancet. 2016;388(10054):1883–92.
17. Yao JJ, Zhang F, Gao TS, Zhang WJ, Lawrence WR, Zhu BT, et al. Survival impact of radiotherapy interruption in nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: a big-data intelligence platform-based analysis. Radiother Oncol. 2019;132:178–87.
18. Yao JJ, Lin L, Jin YN, Wang SY, Zhang WJ, Zhang F, et al. Prognostic value of serum Epstein–Barr virus antibodies in patients with nasopharyngeal carcinoma and undetectable pretreatment Epstein–Barr virus DNA. Cancer Sci. 2017;108(8):1640–7.
19. Yao JJ, Zhou GQ, Wang YQ, Wang SY, Zhang WJ, Jin YN, et al. Prognostic values of the integrated model incorporating the volume of metastatic regional cervical lymph node and pretreatment serum Epstein–Barr virus DNA copy number in predicting distant metastasis in patients with N1 nasopharyngeal carcinoma. Chin J Cancer. 2017;36(1):98.
20. Loong HH, Ma BB, Leung SF, Mo F, Hui EP, Kam MK, et al. Prognostic significance of the total dose of cisplatin administered during concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma. Radiother Oncol. 2012;104(3):300–4.
21. Hong RL, Hsiao CF, Ting LL, Ko JY, Wang CW, Chang JTC, et al. Final results of a randomized phase III trial of induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in patients with stage IVA and IVB nasopharyngeal carcinoma: a multicentre randomised controlled trial. Lancet Oncol. 2016;17(10):1460–70.
22. Yao JJ, Zhou GQ, Wang YQ, Wang SY, Zhang WJ, Jin YN, et al. Prognostic values of the integrated model incorporating the volume of metastatic regional cervical lymph node and pretreatment serum Epstein–Barr virus DNA copy number in predicting distant metastasis in patients with N1 nasopharyngeal carcinoma. Chin J Cancer. 2017;36(1):98.
treatment for nasopharyngeal carcinoma in children and adolescents. Cancer Chemother Pharmacol. 2016;77(2):289–98.

25. Buehrlen M, Zwaan CM, Granzen B, Lassay L, Deutz P, Vorwerk P, et al. Multimodal treatment, including interferon beta, of nasopharyngeal carcinoma in children and young adults: preliminary results from the prospective, multicenter study NPC-2003-GPOH/DCOG. Cancer. 2012;118(19):4892–900.

26. Sahai P, Mohanty BK, Sharma A, Thakar A, Bhasker S, Kakkar A, et al. Clinical outcome and morbidity in pediatric patients with nasopharyngeal cancer treated with chemoradiotherapy. Pediatr Blood Cancer. 2017;64(2):259–66.

27. Rodríguez-Galindo C, Kralio MD, Krasin MJ, Huang L, McCarville MB, Hicks J, et al. Treatment of childhood nasopharyngeal carcinoma with induction chemotherapy and concurrent chemoradiotherapy: results of the children's oncology group ARAR0331 study. J Clin Oncol. 2019;37(35):3369–76.

28. Hui EP, Ma BB, Leung SF, et al. Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma. J Clin Oncol. 2009;27:242–9.

29. Zhang Y, Chen L, Hu QQ, Zhang N, Zhu XD, Yang KY, et al. Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma. N Engl J Med. 2019;381(12):1124–35.

30. Tang C, Wu F, Wang R, Lu H, Li G, Liu M, et al. Comparison between nedaplatin and cisplatin plus docetaxel combined with intensity-modulated radiotherapy for locoregionally advanced nasopharyngeal carcinoma: a multicenter randomized phase II clinical trial. Ann J Cancer Res. 2016;6(9):2064–75.

31. Liu SL, Sun XS, Yan JJ, Chen QY, Lin HK, Wen YF, et al. Optimal cumulative cisplatin dose in nasopharyngeal carcinoma patients based on induction chemotherapy response. Radiother Oncol. 2019;137:83–94.

32. Yao JJ, Qi ZY, Liu ZG, Jiang GM, Xu XW, Chen SY, et al. Clinical features and survival outcomes between ascending and descending types of nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: a big-data intelligence platform-based analysis. Radiother Oncol. 2019;137:137–44.

33. Mertens R, Granzen B, Lassay L, Gademann G, Hess CF, Heimann G. Nasopharyngeal carcinoma in childhood and adolescence: concept and preliminary results of the cooperative GPOH study NPC-91. Gesellschaft für Pädiatrische Onkologie und Hämatologie. Cancer. 1997;80(5):951–9.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.